Metraipolis › archive › dc_ced73caab072

Disproportionality analysis of satralizumab in FDA adverse event reporting system and Japanese adverse drug event report: a pharmacovigilance study — Europe PMC PMID:41613142

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41613142
DOI: 10.3389/fimmu.2025.1647306
License (as archived): solo-consultazione
Archived: 2026-11-06T19:31:01.659Z
SHA-256 of the archived text: df68593738c3f37304f7d55bf2236791ea7f47adfd75fa6ee36b979a3801bdc6
Stable URL of this page: https://metraipolis.com/documento/dc_ced73caab072

How to cite

Disproportionality analysis of satralizumab in FDA adverse event reporting system and Japanese adverse drug event report: a pharmacovigilance study — Europe PMC PMID:41613142 — Europe PMC (en), https://europepmc.org/article/MED/41613142 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ced73caab072 (Metraipolis archive dc_ced73caab072, sha256 df68593738c3f37304f7d55bf2236791ea7f47adfd75fa6ee36b979a3801bdc6)

BibTeX

@misc{dcced73caab072,
  title = {Disproportionality analysis of satralizumab in FDA adverse event reporting system and Japanese adverse drug event report: a pharmacovigilance study — Europe PMC PMID:41613142},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41613142},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ced73caab072; sha256 df68593738c3f37304f7d55bf2236791ea7f47adfd75fa6ee36b979a3801bdc6},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41613142. Agents can read the archived copy with the MCP tool read_document.